Category Archives for "News"

Abattis Bioceuticals Retains Canadian and American Compliance Agency and Provides Company Update

Abattis Retains Canadian and American Compliance Agency and Provides Company Update November 20, 2018    |    Abattis Bioceuticals VANCOUVER, BRITISH COLUMBIA / November 20, 2018 / Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to announce the appointment of Ingredient Identity LLC (“Ingredient Identity”), a Canadian and US regulatory and compliance agency, to assist […]

Read More

Abattis Bioceuticals Celebrates Legalization

Abattis Bioceuticals Celebrates Legalization October 17, 2018    |    Abattis Bioceuticals VANCOUVER, BRITISH COLUMBIA / [October 17, 2018] / Abattis Bioceuticals Corp (the “Company” or “Abattis“) (CSE:ATT) (OTC:ATTBF) is pleased to celebrate the legalization of cannabis in Canada. This is a truly a newsworthy day in Canadian history, as we formally recognize the end […]

Read More

Abattis Bioceuticals Announces Board Changes

Abattis Bioceuticals Announces Board Change October 19, 2018    |    Abattis Bioceuticals VANCOUVER, BRITISH COLUMBIA / October 19, 2018 / Abattis Bioceuticals Corp. (the “Company” or “Abattis“) (CSE:ATT) (OTC:ATTBF) is pleased to announce the addition of Kent McParland and Cedric Wilson to the Board of Directors. Mr. McParland and Mr. Wilson replace Cameron Paddock […]

Read More

Abattis Bioceuticals provides Update on Vaporizer Product Line

ABATTIS BIOCEUTICALS PROVIDES UPDATE ON VAPORIZER PRODUCT LINE October 11, 2018    |    Abattis Bioceuticals Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to announce an update on our recent product line addition of three new vaporizers. Currently, the VB-1, VB-2, CA-2 and the KB-1 have now been made available for purchase […]

Read More

Abattis Bioceuticals Provides Phase 1 Update on Research and Development for Nanoemulsification and Liposomal Platforms of Cannabinoid-Rich Hemp Oil

Abattis Bioceuticals Provides Phase 1 Update on Research and Development for Nanoemulsification and Liposomal Platforms of Cannabinoid-Rich Hemp OilOctober 4, 2018    |    Abattis BioceuticalsAbattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to announce that the research being done in conjunction with the University of British Columbia and Mitacs is close […]

Read More

Abattis unveils “COMFORT” its proprietary New Chronic Pain and Inflammation Product to Start Shipping November 2018

ABATTIS UNVEILS “COMFORT” ITS PROPRIETARY NEW CHRONIC PAIN AND INFLAMMATION PRODUCT TO START SHIPPING NOVEMBER 2018September 24, 2018    |    Abattis BioceuticalsAbattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to announce the pending release of “Comfort”, a nutraceutical designed to target chronic pain and inflammation. As previously announced, the Company hopes […]

Read More